Back to User profile » Dr Gang Wang
Papers published by Dr Gang Wang:
Intramuscular Generic Injection (QLG2072) versus Haloperidol in Chinese Patients with Acute Agitation: A Phase 3 Multicenter, Randomized, Double-Blind, Active-Controlled Trial
Dong F, Wang Z, Li C, Li X, Zhu D, Li J, Wang Z, Gong J, Zhou J, Liu H, Zhang Y, Zhang X, Chen X, Yu M, Tan X, Qian M, Luo Y, Guo WJ, Xie S, Huang J, Zhao J, Wan J, Shan Y, Li N, Wang J, Ju Y, Wang J, Bian Q, Wang G
Drug Design, Development and Therapy 2026, 20:561494
Published Date: 25 February 2026
Unveiling the Interplay Between Depressive Symptoms’ Alleviation and Quality of Life Improvement in Major Depressive Disorder: A Network Analysis Based on Longitudinal Data
Guo T, Feng Y, Zhou J, Meng L, Zhu X, Chen X, Xiao L, Feng L, Zhang L, Xiang YT, Zhao YJ, Wang G
Neuropsychiatric Disease and Treatment 2024, 20:1641-1654
Published Date: 30 August 2024
Resting-State Alpha Activity in the Frontal and Occipital Lobes and Assessment of Cognitive Impairment in Depression Patients
Xie XM, Sha S, Cai H, Liu X, Jiang I, Zhang L, Wang G
Psychology Research and Behavior Management 2024, 17:2995-3003
Published Date: 17 August 2024
The Impact of Depression on Detrimental Changes in Bone Microstructure in Female Mice
Xu H, Sun Z, Wang G, Li R
Neuropsychiatric Disease and Treatment 2024, 20:1421-1433
Published Date: 18 July 2024
Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study
Wang G, Si T, Rieckmann A, Ma J, Christensen MC
Neuropsychiatric Disease and Treatment 2024, 20:1211-1223
Published Date: 7 June 2024
Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study
Wang G, Xiao L, Ren H, Simonsen K, Ma J, Xu X, Guo P, Wang Z, Bai L, Heldbo Reines E, Hammer-Helmich L
Neuropsychiatric Disease and Treatment 2022, 18:1939-1950
Published Date: 30 August 2022
Definition and Identification of Patients with Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia
Han C, Wang G, Chan S, Kato T, Ng CH, Tan W, Zhang L, Feng Y, Liu CY
Neuropsychiatric Disease and Treatment 2020, 16:2929-2941
Published Date: 3 December 2020
Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia
Wang G, Han C, Liu CY, Chan S, Kato T, Tan W, Zhang L, Feng Y, Ng CH
Neuropsychiatric Disease and Treatment 2020, 16:2943-2959
Published Date: 3 December 2020
Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China
Wang G, Si TM, Li L, Fang Y, Wang CX, Wang LN, Tan KHX, Ettrup A, Eriksen HLF, Luo S, Ge L
Neuropsychiatric Disease and Treatment 2019, 15:1723-1736
Published Date: 1 July 2019
Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety
Wang G, You X, Wang X, Xu X, Bai L, Xie J, Yao Z, Yi Q, Ma J, Wang J, Zhuo J, Hu C
Neuropsychiatric Disease and Treatment 2018, 14:2087-2097
Published Date: 14 August 2018
Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Neuropsychiatric Disease and Treatment 2017, 13:2193-2207
Published Date: 17 August 2017
Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study
Wang G, Cheng Y, Wang JN, Wu SH, Xue HB
Neuropsychiatric Disease and Treatment 2016, 12:2077-2087
Published Date: 22 August 2016